Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$13.18

0.48 (3.78%)

13:05
07/14/17
07/14
13:05
07/14/17
13:05

Horizon Pharma call volume above normal and directionally bullish

Bullish option flow detected in Horizon Pharma with 3,558 calls trading, 3x expected, and implied vol increasing over 1 point to 54.66%. Aug-17 11 calls and Aug-17 14 calls are the most active options, with total volume in those strikes near 3,100 contracts. The Put/Call Ratio is 0.07. Earnings are expected on August 7th.

  • 07

    Aug

HZNP Horizon Pharma
$13.18

0.48 (3.78%)

06/16/17
CANT
06/16/17
INITIATION
Target $13
CANT
Overweight
Horizon Pharma initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Horizon Pharma with an Overweight rating and $13 price target.
06/07/17
UBSW
06/07/17
NO CHANGE
Target $16
UBSW
Buy
Horizon Pharma weakness a buying opportunity, says UBS
UBS analyst Marc Goodman believes the recent downward move for Horizon Pharma shares was due to frustration by investors who have grown tired of the lack of performance by the company, management's lowered guidance due to lack of visibility, and problems with the company's primary care businesses. Goodman believes the recent weakness is a buying opportunity, though he lowered his price target to $16 from $22 based on his sum-of-the-parts valuation. Goodman maintained his Buy rating on Horizon Pharma shares.
05/09/17
05/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cisco (CSCO) downgraded to Market Perform from Outperform at BMO Capital with analyst Tim Long saying that the company is facing "share losses in switching and a struggling router market," along with a "contracting" data center business. The analyst says that the company is having difficulty growing its core businesses. 2. DSW (DSW) downgraded to Neutral from Buy at Buckingham with analyst Scott Krasik saying he believes the company's competitive positioning has eroded over the last few years even amid department stores' "demise" playing out. 3. Horizon Pharma (HZNP) downgraded to Neutral from Buy at Mizuho. 4. ChannelAdvisor (ECOM) downgraded to Equal-Weight from Overweight at First Analysis. 5. Realogy (RLGY) downgraded to Neutral from Buy at Compass Point with analyst Frederick Small raising his price target for the shares to $32 from $31. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/17
STFL
05/09/17
NO CHANGE
STFL
Horizon Pharma price target lowered to $20 from $35 at Stifel
Stifel analyst Annabel Samimy cut her price target on Horizon after the company reported weaker than expected results and lowered its guidance, citing weakness in its primary care business. Noting that Horizon has decided to "accelerate its transition to an Orphan/Specialty story," the analyst now only ascribes value "to this value/growth driving portion of the business." However, she keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.